Perceptive Informatics, the technology subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has appointed Mr. Sina Adibi to the position of Vice President of Software Development and Chief Technology Officer.
Mr. Adibi brings more than 20 years of global technology experience to Perceptive Informatics, which provides innovative technology-based solutions designed to help bio/pharmaceutical companies accelerate clinical development. In addition to driving strategic direction for product planning and architecture, Mr. Adibi is responsible for all of Perceptive's software development to support and strengthen its eClinical offerings including clinical trial management software (IMPACT(TM) and INITIATOR(TM)), interactive voice response systems, and medical imaging.
"As bio/pharmaceutical clients increasingly seek technology solutions to further streamline clinical development, PAREXEL continues to increase its investment in Perceptive's technology platforms," said Todd Joron, Corporate Vice President and General Manager of Perceptive Informatics. "We expect Mr. Adibi's leadership and expertise to benefit Perceptive through his extensive international experience in software development and successful management of large scale technology implementations."
"I am pleased to be joining a clear leader in providing advanced technologies to the bio/pharmaceutical industry," said Mr. Adibi. "I look forward to contributing to Perceptive's innovation as we continue to deliver products and services that help clients bring increased efficiencies to the management of clinical trials."
Mr. Adibi joins Perceptive Informatics from the Thomson Scientific Division of Thomson Publishing where he served as Senior Vice President and Chief Technology Officer, leading an international software development team. In this role, he oversaw product management, software development, and software validation and was responsible for several large scale technology acquisitions. Mr. Adibi holds Bachelor's and Master's degrees in computer science from Temple University in Pennsylvania.
Mr. Adibi is based at the Lowell, Massachusetts location of Perceptive Informatics.
About Perceptive Informatics, a PAREXEL Company
PAREXEL's Technology Division, Perceptive Informatics, combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive's portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive's market-leading CTMS product with 25,000 users worldwide, and Perceptive's INITIATOR(TM) trial management product targets the needs of Phase I units. For more information about Perceptive Informatics, visit http://www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 56 locations throughout 43 countries around the world, and has over 6,215 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2006 as filed with the SEC on February 9, 2007, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Jennifer Baird, Director of Public Relations